Lumos Pharma (LUMO)
(Delayed Data from NSDQ)
$2.52 USD
0.00 (0.00%)
Updated Apr 17, 2024 03:58 PM ET
After-Market: $2.58 +0.06 (2.38%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LUMO 2.52 0.00(0.00%)
Will LUMO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for LUMO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LUMO
UniQure (QURE) Reports Q4 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates
LUMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lumos Pharma (LUMO) Reports Q3 Loss, Lags Revenue Estimates
Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Top Estimates
Other News for LUMO
Lumos Pharma’s LUM-201 Receives ‘Buy’ Rating on Strong Market Position and Promising Trial Outcomes
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
Lumos Pharma receives notice of allowance from USPTO for LUM-201 patent
Analysts Are Bullish on Top Healthcare Stocks: Poseida Therapeutics (PSTX), Lumos Pharma (LUMO)
Analysts Are Bullish on Top Healthcare Stocks: Lumos Pharma (LUMO), Arcturus Therapeutics (ARCT)